Results 151 to 160 of about 20,740 (205)

Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells. [PDF]

Hematol Transfus Cell Ther
Avinery L, Regev D, Khamaisi H, Gopas J, Mahajna J.   +4 more
europepmc   +1 more source

Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics. [PDF]

Front Pharmacol
Alqahtani S.
europepmc   +1 more source

Rare Atypical Ela3 BCR-ABL transcript in acute Lymphoblastic Leukemia: a case report. [PDF]

Afr Health Sci
Xu L, Han T, Wei S, Wang N.
europepmc   +1 more source

The silent players: Atypical <i>BCR‑ABL </i>isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review). [PDF]

Oncol Rep
Zhou X, Li A, Kong D, Shi Y, Zhang P, Shan N.   +5 more
europepmc   +1 more source

Allosteric PROTACs: Expanding the Horizon of Targeted Protein Degradation. [PDF]

J Am Chem Soc
Frost A, O'Connor S, Ciulli A.
europepmc   +1 more source

Unveiling Cryptic <i>BCR-ABL1</i> Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies. [PDF]

Int J Mol Sci
Ferrari A, Salvesi C, Fonzi E, Giannini B, Tonelli M, Zacheo I, Paganelli M, Lo Schiavo F, Rosetti M, Simonetti G, Marconi G.   +10 more
europepmc   +1 more source

The autophagy switch: A critical determinant of arsenic-induced carcinogenesis and cancer therapy. [PDF]

Toxicol Rep
Zeinvand-Lorestani M, Rahim F, Zeinvand-Lorestani H.   +2 more
europepmc   +1 more source

Concurrent NPM1::CCDC28A and BCR::ABL1 fusions in extramedullary blast crisis of chronic myeloid leukemia: A case report and literature review. [PDF]

Ann Hematol
Zhu L, Yi K, Zhou J, Hu G, He J, Lan H, Chen M, Sun L, Zheng B, Li R.   +9 more
europepmc   +1 more source

Rapid and sensitive acute leukemia classification and diagnosis platform using deep learning-assisted SERS detection. [PDF]

Cell Rep Med
Zhang D, Cheng Z, Song Y, Li H, Shi L, Wang N, Peng Y, Chen R, Sun N, Han M, Hu F, Zong C, Zhang R, Chen S, Zhu C, Zhang X, Li X, Ma X, Shi C, Zhang X, Liu R, Ren Z, Wang L, Zeng Q, Zeng T, Chen X.   +25 more
europepmc   +1 more source

Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. [PDF]

Cancer Rep (Hoboken)
Gangadaran N, Mamlekar H, Saha S, Kashyap R, Yadav S, Rahman K, Gupta R, Vijayaran M, Singh M, Chandra D.   +9 more
europepmc   +1 more source